Sitagliptin (DPP-4 Inhibitor) and Bedtime NPH Insulin as Third-Line Antidiabetic Agents in Patients with Type 2 Diabetes (DM2) Inadequately Controlled with Sulfonylurea and Metformin.
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2015
At a glance
- Drugs Insulin suspension isophane (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Jun 2011 New trial record